How Avelumab Targets Renal Cell Carcinoma
Avelumab (brand name Bavencio) treats advanced renal cell carcinoma (RCC), a kidney cancer, by harnessing the immune system to attack cancer cells. As a fully human anti-PD-L1 IgG1 monoclonal antibody, it binds to PD-L1 on tumor cells and immune cells, blocking its interaction with PD-1 on T cells. This inhibition prevents tumor evasion of immune detection, reactivating cytotoxic T cells to destroy cancer cells.[1][2]
In RCC, tumors often overexpress PD-L1, suppressing immune responses. Avelumab restores this balance, promoting T-cell infiltration and tumor killing without directly damaging healthy tissue.[3]
FDA Approval and Clinical Evidence
The FDA approved avelumab in 2021 for first-line treatment of advanced RCC, combined with axitinib (Inlyta), a tyrosine kinase inhibitor targeting VEGF receptors. This regimen showed superior progression-free survival versus sunitinib in the phase 3 JAVELIN Renal 101 trial: median 13.8 months vs. 8.4 months (HR 0.69; p<0.001), with overall survival trends favoring the combo (HR 0.78).[2][4]
Monotherapy approval came earlier for Merkel cell carcinoma, but RCC use relies on the combo due to axitinib's anti-angiogenic effects complementing immune checkpoint blockade.[1]
How It Compares to Other RCC Immunotherapies
Avelumab-axitinib outperforms sunitinib but trails slightly behind pembrolizumab-axitinib (KEYNOTE-426: PFS 15.1 months) and nivolumab-cabozantinib (CABOSUN/CheckMate 9ER: PFS 16.6 months) in head-to-head PFS data. All target PD-1/PD-L1 pathways, but differences lie in partners: axitinib enhances vascular normalization for better T-cell access.[4][5]
| Regimen | Median PFS (months) | OS HR vs. Sunitinib |
|---------|---------------------|---------------------|
| Avelumab + Axitinib | 13.8 | 0.78 |
| Pembrolizumab + Axitinib | 15.1 | 0.73 |
| Nivolumab + Cabozantinib | 16.6 | 0.66 |
PD-L1 status predicts response across agents, with higher expression linked to better outcomes.[3]
Common Side Effects and Patient Risks
Immune-related adverse events dominate: fatigue (50%), hypertension (40% from axitinib), diarrhea (30%), and thyroid issues (25%). Severe cases include immune-mediated pneumonitis (1-2%), colitis, or hepatitis, managed with corticosteroids.[2] RCC patients with liver metastases face higher hepatotoxicity risks.
Who Makes Avelumab and Patent Status
Pfizer and Merck KGaA co-develop and market Bavencio. U.S. patents cover the antibody sequence and RCC use through 2031-2036, with extensions possible; challenges from biosimilar makers are pending.[6]DrugPatentWatch.com
Sources
[1]: Bavencio Prescribing Information, FDA (2023) - link
[2]: Choueiri et al., Lancet (2019), JAVELIN Renal 101 - link
[3]: NCCN Guidelines, Kidney Cancer v.2.2024 - link
[4]: Motzer et al., NEJM (2019), KEYNOTE-426 - link
[5]: Choueiri et al., NEJM (2021), CheckMate 9ER - link
[6]: DrugPatentWatch.com, Bavencio Patents - link